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The 4th Global Forum on TB Vaccines, convened in Shanghai, China, from 21 e 24 April 2015, brought
together a wide and diverse community involved in tuberculosis vaccine research and development to
discuss the current status of, and future directions for this critical effort. This paper summarizes the
sessions on Advancing the Pipeline: A Vision for the Next Decade, Engaging the BRICS: Basic Research
to Manufacturing, and Regulatory and Access Issues for New TB Vaccines. Summaries of all sessions
from the 4th Global Forum are compiled in a special supplement of Tuberculosis. [August 2016, Vol 99,
Supp S1, S1eS30].
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
When world leaders adopted the Millennium Declaration in
September 2000, they included speciﬁc targets to halt and begin to
reverse the incidence of tuberculosis (TB). The Millennium Decla-
ration was followed by new initiatives to overcome the structural
and ﬁnancial obstacles for developing new TB vaccines, backed by
support from public and philanthropic sources. These initiatives
included the establishment of dedicated product development
partnerships (PDPs) such as Aeras and the TuBerculosis Vaccine
Initiative (TBVI), publicepublic partnerships like the European &
Developing Countries Clinical Trials Partnership (EDCTP), and
dedicated programs by major research funding agencies. Fifteen
years later, the TB vaccine research ﬁeld has arrived at the right
momentdscientiﬁcally and politicallydto review progress and
reﬂect on the best ways to move forward. To anticipate the next
decade of TB vaccine research and development (R&D), speakers at
the 4th Global Forum presented perspectives on how scientiﬁc
advances, advocacy and resource mobilization challenges, the
increasingly important role of the BRICS (Brazil, Russia, India, China,Butantan Institute, Av. Vital
816.
.C. Leite).
Ltd. This is an open access articleSouth Africa) countries, and regulatory and access issues might
affect research for new TB vaccines.2. Advancing the pipeline: a vision for the next decade
During the ﬁnal plenary session of the 4th Global Forum, Dr.
Laurent Bochereau (Delegation of the European Union to China), Dr.
Willem Hanekom (Bill & Melinda Gates Foundation, USA), Prof.
Michel Kazatchkine (UN Secretary-General's Special Envoy on HIV/
AIDS in Eastern Europe and Central Asia, Switzerland), Dr. Kei
Katsuno (Global Health Innovative Technology Fund, Japan), and Dr.
Ole Olesen (EDCTP, the Netherlands) discussed the global envi-
ronment for TB vaccine R&D and how it could be improved in the
next decade. This section summarizes key points from that
discussion.2.1. Mobilizing resources, promoting collaboration, and broadening
the base of support
A large proportion of TB vaccine R&D funding comes from the
public sector and from philanthropic organizations, while industry
investments comprise less than 20% of global funding [1]. With an
annual investment of approximately US$45 million, the Bill &
Melinda Gates Foundation (Gates Foundation) is currently the
world's largest funder of TB vaccine R&D, while the Europeanunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Funding for preventive TB vaccine R&D by year and funder category,
2007e2014.
Data source for ﬁgure: G-FINDER Public Search Tool [1].
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governments constitute the largest public funders of TB vaccine
R&D. Together, these six sources provided 75% of total global
funding for TB vaccine R&D from 2007 to 2014 [1]. During this
period, total global investment for preventive TB vaccine R&D
hovered around US$110 million per year (Figure 1) [1], which is
only about 15% of the average investment in preventive HIV vac-
cines in that same timeframe [1]. Low- and middle-income coun-
tries contribute more than half of global gross domestic product
(GDP) and carry the vast majority of TB disease burden, but their
ﬁnancial contribution to TB vaccine R&D remains negligible.
Developing an effective TB vaccine represents a global endeavor,
requiring broad ownership, a wider andmore diverse funding base,
and further involvement of and collaboration between researchers,
clinicians, manufacturers, civil society, and affected communities.
To make this goal a reality, the EU has recently supported two large
four-year collaborative projects on preclinical TB vaccine research,
TBVAC2020 and EMI-TB, utilizing V26 million from the Horizon
2020 program. In addition, the EDCTP2 program is expected to
disburse more than V1.4 billion over the next 10 years for clinical
trials in sub-Saharan Africa, including TB vaccine trials. At the time
of the Global Forum, the Global Health Innovative Technology Fund
(GHIT Fund) had invested over US$35 million in nearly 40 collab-
orative research projects between Japanese and non-Japanese or-
ganizations with a focus on infectious diseases prevalent in
developing countries, including funding of US$5.7 million for work
on a novel vaccine candidate to combat TB. The Gates Foundation
has established a new consortium called the Collaboration for TB
Vaccine Discovery (CTVD) to promote innovation in the upstream
research space through discussion forums and early data-sharing,
by leveraging co-funding of the TB vaccine ﬁeld by various fund-
ing stakeholders, and by providing service platforms to facilitate
state-of-the-art science.
While dedicated funding opportunities exist for TB vaccine R&D,
they are far from sufﬁcient to support the intensive basic science,
preclinical and clinical investigations necessary to efﬁciently move
the ﬁeld forward in a manner commensurate with the extent of dis-
ease and death caused by TB. TB vaccine R&D has to compete for
sufﬁcient attention with many other diseases and social problems.
Funders and decision-makers must be convinced that new, more
effective TB vaccineswould not only be a highly cost-effective tool for
improving global public health, but also that their investments will
return value for funding. Further, speakers voiced the need to estab-
lish a global advocacy plan which would allow a broad array of
stakeholders to communicate with policy makers in a coherent,
consistent, and more efﬁcient manner, while avoiding thefragmentation and rivalry that sometimes has hindered progress in
other scientiﬁc areas. Speakers also emphasized the need for the TB
vaccines community to advance a bolder, more innovative research
agenda, learning fromexperiences in otherdisease areas, such asHIV.
2.2. Advancing the science
Funding and broader ownership of R&D will be driven by sci-
entiﬁc innovation, by progress in developing new TB vaccines, and
by demonstrating that TB vaccine research can be deployed in a
cost-efﬁcient manner. To achieve this, vaccine candidates should be
de-risked at earlier stages of development to ensure that limited
resources are applied to the advancement of candidates with the
greatest likelihood of success. Target product proﬁles should guide
the product development pathway. At the same time, the potential
for generating more diversity in the types of immunologic re-
sponses beyond classical CD4þ and CD8þ T-cell responses gener-
ated by TB vaccine candidates needs to be explored. The potential
effect of heterogeneity in both human populations and tuberculosis
strains on the efﬁcacy of candidate TB vaccines should also be
addressed. Better animal models, the identiﬁcation of correlates of
protection, and early proof-of-concept vaccine trials will help
determine if a vaccine has the desired clinical proﬁle before
entering large and costly phase 2b/3 clinical efﬁcacy trials. This
ideally would be done through an efﬁcient, transparent, and
rigorous gating system to compare, select, and advance the most
promising vaccines candidates towards a ﬁnal product. In 2012,
TBVI and Aeras took the ﬁrst step in this direction by developing a
set of consensus stage-gating criteria to inform advancement of TB
vaccine candidates at each step of the development pipelinedfrom
discovery work to phase 3 trials [2]. At the time of the Global
Forum, discussions were underway to establish a Global TB Vaccine
Partnership (GTBVP), which would adopt and expand this stage
gate approach to provide advice to a broader constituency of fun-
ders, researchers and industry groups involved in TB vaccine R&D
across the globe.
3. Engaging the BRICS: from basic research to manufacturing
During a plenary session focused on better engaging the BRICS
countries in TB vaccine R&D, Dr. Luciana Leite (Butantan Institute,
Brazil), Dr. Soumya Swaminathan (Indian Council for Medical
Research, India), Dr. Bi Lan (China National Biotech Group, China),
and Prof. Gavin Churchyard (Aurum Institute, South Africa) dis-
cussed the respective BRICS countries' capacities for research,
development, manufacturing and clinical trials of TB vaccines.
Together the BRICS countries comprise 40% of the world's popula-
tion and 20% of the world's GDP, and share socio-economic and
environmental issues that contribute to the high burden of TB.
Collectively, the BRICS countries account for almost 50% of reported
TB cases globally [3]. Each of these countries, however, has signif-
icantly different levels of experience and capabilities for conducting
TB vaccine R&D.
In Brazil and India, most TB vaccine R&D is conducted in aca-
demic and government research centers and is focused on discov-
ery and preclinical phases. China and South Africa have
development programs through national grants for R&D of novel
TB vaccines. China is supporting the development of new or
improved TB vaccine candidates, including recombinant BCG
(rBCG) as a BCG replacement, and prime/boost vaccines in collab-
oration with international partners. South Africa has established
the Strategic Health Innovation Partnerships (SHIP) program, under
the Medical Research Council (MRC), with the mission to seek, fund
and manage multi-disciplinary and multi-institutional product
research, development and innovation projects from prototype to
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the ﬁeld. The SHIP program is sponsoring several TB vaccine and TB
biomarker related projects.
Most BRICS countries have considerable experience with and
capacity for vaccine manufacturing. Many of their respective na-
tional regulatory authorities (NRAs) and several of their
manufacturing facilities have been prequaliﬁed by the World
Health Organization (WHO). Capacity for translation of R&D into
products, however, has been limited, although this challenge is not
unique to BRICS countries.
Most BRICS countries also have signiﬁcant capacity to conduct
clinical trials. In Brazil, clinical studies demonstrated that two doses
of BCG were not signiﬁcantly better than one [4]. India conducted
the largest TB vaccine trial in the world, the Chingleput Trial of BCG
vaccine, which assessed the effect of environmental non-TB
mycobacteria on vaccine efﬁcacy and TB disease [5,6]. In China, a
Mycobacterium vaccae vaccine candidate is currently in a phase 3
clinical trial seeking to prevent TB disease. This trial has enrolled
10,000 volunteers; ﬁnal results are expected in the second half of
2016. South Africa is working with WHO to become a model
country in the prevention and treatment of TB, and has several
clinical trial sites that have conducted numerous investigator
initiated TB vaccine trials in HIV-uninfected and infected persons.
Advocacy efforts are being stepped-up, with initiatives to in-
crease the visibility of the enormous but often “hidden” TB burden,
and to prompt discussion of policies for dealing with this problem
in all BRICS countries. In Brazil, the Rede TB network has taken the
TB vaccine discussion to the government and media. India has
made high-level commitments awaiting translation into practice
on the ground. South Africa has a strong legacy of advocacy on TB
drug development. The TB Think Tank, created in response to
Nelson Mandela's call to ﬁght TB alongside HIV, has issued a series
of policy papers on the need for TB drugs. This could be used as a
voice for support of TB vaccine R&D as well.
Partnerships are an important component of R&D strategies
against TB. India's clinical trial sites recognize the value of sharing
samples within collaborations. In South Africa and other BRICS
countries, international co-funding routinely is requested to sup-
port clinical trials, making these initiatives dependent on com-
plementing external resources. The Developing Countries Vaccine
Manufacturers Network (DCVMN) includes BRICS countries and
organizes annual meetings to discuss common problems and op-
portunities to collaborate in vaccine manufacturing. The market
power of BRICS countries is signiﬁcant; extending cooperationwith
other countries will be important to take full advantage of this
inﬂuence.
On the whole, TB epidemiology and diagnosis of TB, together
with clinical trials capacity, are increasingly well established in the
BRICS, but timely R&D for TB vaccines will require increased global
collaboration and partnership between public and private organi-
zations, industry, governments, and civil society as well as collab-
orations and resource-sharing between BRICS countries
themselves. Funding mechanisms will require mobilization of a
wide array of sectors to support TB vaccine R&D, as well as crea-
tivity in ﬁnding sustainable mechanisms and additional resources
for support. Compared to TB drugs or HIV vaccines, advocacy for TB
vaccines is lagging, which merits urgent attention in order to ﬁnd
additional resources.
Following the discussion on the BRICS contribution toTB vaccine
R&D, Dr. Haibin Niu (Shanghai Institutes for International Studies,
China) provided his perspectives on the BRICS role in global public
health. He noted the importance of the BRICS countries to global
public health, given their population, their increasing ﬁnancial re-
sources and technology capacity, and their growing inﬂuence in the
global governance system. He identiﬁed some of the advantagesand challenges of the BRICS countries and noted several key aspi-
rational contributions to global health, including: 1) improving
domestic health within the BRICS, which would have an impact on
global health given their population; 2) enhancing international
collaborations; 3) institutionalizing the BRICS health ministers
meeting; 4) increasing government support for health; 5)
leveraging their involvement in the post-2015 agenda negotiations
to focus on health issues; and 6) emphasizing North-South col-
laborations alongside SoutheSouth collaboration.
4. Regulatory and access issues for new TB vaccines
In the plenary session on regulatory and access issues in TB
vaccine R&D, speakers offered perspectives on reviewing and
approving new drugs and biologics for neglected diseases and the
need to anticipate access challenges common to low resource set-
tings when designing new vaccines. Despite diverse perspectives, a
common theme emerged: the importance of early engagement by
researchers and product developers with regulatory authorities,
vaccine end-users (i.e., public health systems and private and non-
governmental medical providers) and TB-affected communities.
Engagement with TB-affected communities is particularly
important given that vaccines can only reach their full potential
when they are accepted and taken up by the community.Withwide
coverage, a vaccine may also protect individuals beyond those who
are immunized directly, an important principle of vaccination
called herd-immunity. Community acceptance of new TB vaccines
and support for TB vaccine R&D is crucial for ensuring that scientiﬁc
advances in the pipeline translate into public health impact. The
promise attributed to vaccines also stems from their reputation as
one of the most cost-effective public health interventions. Citing
data compiled by Medecins Sans Frontieres (MSF), Dr. Lucia Fer-
nandez Aleixo (MSF, China) warned that a key determinant of
vaccine cost-effectivenessdaffordabilitydcan no longer be taken
for granted. The cost to fully immunize a child with vaccines
included in the WHO's Expanded Program on Immunization (EPI)
increased from $0.67 in 2001 to $45.59 in 2014da 68-fold rise. New
vaccines licensed within the last decade comprise over 85% of the
total cost [7]. Consequently, product developers will need to think
carefully about the affordability of new TB vaccines in the context of
the rising overall costs of immunization packages. From MSF's
perspective, access requires more than ﬁnding an affordable price
point; new TB vaccines should also be ﬁeld adapted to meet the
needs of health systems and providers. Optimally, such vaccines
would be heat-stable, needle-free, single-dose, packaged to
generate minimal waste and have a long shelf life.
Dr. Roshan Ramanathan (Center for Biologics Evaluation and
Research, Food and Drug Administration, USA) stated that the FDA
has the authority to approve marketing applications for biological
products intended to treat, mitigate, diagnose, or prevent condi-
tions or diseases found in the U.S. as well as diseases or conditions
primarily endemic to other countries including those that have not
been reported to occur in the U.S [8]. Dr. Ramanathan also discussed
FDA programs intended to facilitate and expedite development and
review of new biologics to address unmet medical needs in the
treatment of serious or life-threatening diseases or conditions.
These programs include fast track designation, breakthrough
therapy designation, accelerated approval, and priority review
designation [9]. Information about these FDA programs is provided
in the US FDA Guidance for Industry: Expedited Programs for
Serious Conditions e Drugs and Biologics [9].
The lack of regulatory harmonization across countries has often
been identiﬁed as a barrier to rapid testing and uptake of new TB
vaccines, but efforts are being made at regional levels to ameliorate
this. Morakot Papassiripan (Food and Drug Administration,
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tions in the Southeast Asia region through the Association of
Southeast Asian Nations (ASEAN) Pharmaceutical Product Working
Group. The group has sought to align technical guidelines and
regulatory requirements and has developed common technical
documents with a view toward mutual recognition agreements
between regulatory agencies of ASEAN member states.
Dr. Miao Xu (National Institutes for Food and Drug Control e
NIFDC, China) provided a perspective on the preclinical evaluation
of TB vaccines in China. Dr. Xu stressed the importance of devel-
oping new TB vaccines for China, given the high national TB burden,
and speciﬁcally cited the need for vaccines that prevent Mtb
infection and TB disease, and the importance of developing vac-
cines to boost the prime BCG. She noted that NIFDC followed
quality evaluation guidances similar to those in the Rational
approach to selection and clinical development of TB vaccine candi-
dates Blueprint for TB Vaccines: A Strategic Blueprint for the Next
Decade [10,2]. However, she also cited some important differences
between them, notably that the rational approach suggests survival
rate and colony-forming units (CFUs) should represent the key
criteria when assessing vaccines in the preclinical phase while
China's guidance focuses instead on gross pathology as well as CFU
determinations. NIFDC's also attaches importance on assessing
vaccine candidates for their potential to elicit a Koch reaction, a
vaccine-induced inﬂammatory reaction when administered to an-
imals or individuals infected with Mtb, which is not included in the
rational approach and the Blueprint. Additionally, the NIFDC pre-
clinical efﬁcacy evaluation in China notes that safety and efﬁcacy
evaluations should be carried out in different animal models, with
the extent of CFU suppression in a challenge model representing a
key indicator.
The regulatory and access presentations at the 4th Global Forum
demonstrated the importance of anticipating regulatory and access
challenges early in the vaccine development process. Such antici-
pation should go beyond consultations with technical experts to
also gather information on the needs, priorities, and challenges of
health providers and the communities that will host and partici-
pate in TB vaccine research.
5. Conclusion
Many scientiﬁc, regulatory, and political challenges remain in
the development of new TB vaccines, and Michel Kazatchkine, in
his remarks to the Forum, encouraged those involved in TB vaccine
R&D to consider the role of global partnerships and mobilization in
overcoming these challenges. Speciﬁcally, he urged Forum dele-
gates to frame a new TB vaccine as a global public health good.
Achieving this will require science advancing in pace with new
forms of solidarity. Scientists themselves must make efforts to
include civil society, TB-affected communities, and activist net-
works as key partners in the R&D process. Simultaneously, the
small band of advocates already supporting TB R&D must work to
link this cause to bigger social movements advocating for health,
sustainable development and an end to poverty. Activists working
on HIV, human rights, gender equality, poverty reduction, access to
medicines, and allied issues must be mobilized to include thedevelopment of new TB vaccinesdand the ﬁght against TB in
generaldas instrumental to their own causes. More frequent
communications between the scientiﬁc and advocacy communities
would better equip advocates to relay information to others,
represent TB vaccine science in front of country governments, and
communicate the potential of TB vaccine R&D to signiﬁcantly
advance the cause of improving global public health.
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